NCT01744808已完成1 期
A Phase 1 Study To Investigate the Pharmacokinetics of SR Formulations; and the Food Effect, Safety, Tolerance, Pharmacokinetic and Pharmacodynamic Profile Of 1 SR Formulation of EB-1020 In Young Healthy Subjects
Otsuka Pharmaceutical Development & Commercialization, Inc.1 个研究点 分布在 1 个国家目标入组 54 人开始时间: 2013年2月1日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 54
- 试验地点
- 1
- 主要终点
- Cmax
研究概览
简要总结
To investigate whether there is a food-effect with oral administration with EB-1020 as well as to obtain information on the safety, and tolerability of EB-1020 in a range of doses.
详细描述
- To investigate the safety and tolerance of single doses of EB-1020 immediate release (IR) versus three sustained release (SR) formulations.
- To investigate the safety and tolerance of a single oral dose of a SR formulation of EB-1020 in the fed and fasted state.
- To investigate the safety, tolerance, and cognitive effects of multiple oral rising doses of a SR formulation of EB-1020.
Secondary Objectives
- To characterize the single dose and steady state pharmacokinetic profiles of EB-1020 SR formulations.
- To investigate the effect of food on the pharmacokinetic profile of EB-1020 SR following single oral doses.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Aged 18-45 years inclusive
- •Body weight with the normal range for height (body mass index [BMI] between 19-30 kg/m2 inclusive)
- •If female, be of non-child bearing potential (surgically sterile, post-menopausal for 12 months or receiving a stable dose of implanted or injectable contraceptive for at least 3 months with last dose of injectable contraceptive within 2 months). Non-surgical menopause history must be confirmed by follicle-stimulating hormone (FSH) and luteinizing hormone (LH) levels as defined by established lab ranges.
- •Be in general good health without clinically significant medical history
- •Have clinical laboratory test results that are within the laboratory reference range; or if out of range are not clinically relevant and are acceptable to the Investigator and Sponsor medical representative
- •Negative Human Immunodeficiency Virus (HIV), Hepatitis B and Hepatitis Screening test
- •Able and willing to give written informed consent
排除标准
- •Receipt of any investigational agent or drug within 3 months of entry into the study
- •Use of prescription drugs within 4 weeks prior to first dosing. Subjects who have used over the counter medication excluding paracetamol, topical over the counter medications and routine vitamins but including megadose (intake of 20 to 600 times the recommended daily dose) vitamin therapy within 7 days of first dosing, unless agreed as non-clinically relevant by the Principal Investigator and Sponsor
- •A history of, or current evidence for, suicidal ideation, based upon clinical interview and a psychiatric questionnaire
- •A history of known or suspected seizures, spasms, infantile spasms, febrile convulsions, unexplained significant and recent loss of consciousness or history of significant head trauma with loss of consciousness or a family history (first degree relative) of epilepsy or seizures (fits)
- •A history of sleep problems in the last 3 months
- •A history of relevant atopy or drug hypersensitivity
- •A history (within the last 5 years) or evidence of alcohol or drug abuse. Subject who consume more than 14 units (female) or 21 (male) units of alcohol a week (unit = 1 glass (125 mL) of wine = 1 measure of spirits = ½ pint of beer) will also be ineligible
- •A positive urine test for drugs of abuse or alcohol at Screening or on the day of admittance to the Study Unit
- •A history of smoking in the last 3 months
- •Have a significant infection (such as influenza) or known inflammatory process on screening or admission
- •Have acute gastrointestinal symptoms at the time of screening or admission (e.g. nausea, vomiting, diarrhea, heartburn )
- •Have previously received EB-1020
- •Be vegetarians, vegans or have medical dietary restrictions
- •Any major surgical procedure within one month of entry into the study
- •Have difficulties communicating reliably with the Investigator or appear unlikely to co-operate with the requirements of the study in the investigator's judgment.
- •Any other condition which in the view of the Investigator is likely to interfere with study or put the subject at risk.
研究组 & 干预措施
EB-1020 SR1
Active Comparator
Sustained release formulation
干预措施: EB-1020 SR1 (Drug)
EB-1020 SR2
Active Comparator
Sustained Release Formulation
干预措施: EB-1020 SR2 (Drug)
EB-1020 SR3
Active Comparator
Sustained Release Formulation
干预措施: EB-1020 SR3 (Drug)
EB-1020 IR
Active Comparator
Immediate Release Formulation
干预措施: EB-1020 IR (Drug)
Placebo
Placebo Comparator
Placebo Formulation
干预措施: Placebo (Other)
结局指标
主要结局
Cmax
时间窗: up to 6 months
Pharmacokinetic parameters
Tmax
时间窗: up to 6 months
Pharmacokinetic parameter
AUC
时间窗: up to 6 months
Pharmacokinetic parameter
次要结局
- Effect of food on Cmax(up to 6 months)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Study in Healthy People to Test How BI 1015550 is Taken up in the Body When Given With or Without FoodHealthyNCT06415045Boehringer Ingelheim18
已完成
1 期
A Study to Assess the Effect of Food With Fezolinetant in Healthy Female ParticipantsHealthy SubjectsNCT04641260Astellas Pharma Global Development, Inc.16
已完成
1 期
Relative Bioavailability of BI 1015550 Following Oral Administration Under Fed and Fasted Conditions in Healthy Male SubjectsHealthyNCT03302078Boehringer Ingelheim12
已完成
1 期
Pharmacokinetics and Food Effect of Single Oral Dose of E7050 in Healthy VolunteersHealthy SubjectsNCT02533102Eisai Limited42
已完成
1 期
A Open-label Food Effect Study With SEN0014196 in Subjects With Huntington DiseaseHuntington's DiseaseNCT01485965Siena Biotech S.p.A.26